Petros Pharmaceuticals

Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Common Stock Will Begin Trading on Split-Adjusted Basis on December 1, 2022 NEW YORK, NY / ACCESSWIRE / November 30, 2022 / Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (Nasdaq:PTPI), a leading provider of therapeutics for men's health, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will become effective at 4:05 p.m.

Petros Pharmaceuticals Announces Reverse Stock Split

NEW YORK, NY / ACCESSWIRE / November 15, 2022 / Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announced financial results for the third quarter ended September 30, 2022. Recent Highlights: Company reported results of an Indian study published in the International Journal of Urology , in which patients reported improvement in erectile function compared to sildenafil and baseline after 12 weeks of therapy, onset of action within 15 minutes and a significant percentage of patients reaching normal erectile function according to their IIEF-EF score FDA approval of an expansion of the STENDRA label that now includes positive clinical trial data on STENDRA ® (avanafil) use by men with ED who have undergone radical prostatectomy.

Petros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Update

Expanded STENDRA Labeling Now Includes Data on a Significant Population of Men Not Previously Included Following Submission of Additional Clinical Trial Data NEW YORK, NY / ACCESSWIRE / October 25, 2022 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a leading provider of therapeutics for men's health, today announces the expansion of the FDA labeling for its oral erectile dysfunction (ED) drug, STENDRA® (avanafil), marketed by its subsidiary, Metuchen Pharmaceuticals. The expanded label now includes positive clinical trial data on STENDRA® (avanafil) use by men with ED who have undergone radical prostatectomy.

New FDA-Approved Labeling for Petros Pharmaceuticals' STENDRA (avanafil) Now Includes Efficacy Data Regarding Use in Men Who Have Undergone Radical Prostatectomy

NEW YORK, NY / ACCESSWIRE / October 21, 2022 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will participate in two October 2022 conferences. LD Micro Main Event XV (Los Angeles, CA) Presentation Date: Tuesday, October 25Time: 4:30 pm PT (Track 4) The conference is being held on October 25 - 27, 2022 at the Luxe Sunset Boulevard Hotel in Los Angeles.

Petros Pharmaceuticals to Participate in Two October 2022 Conferences

Data Published in the "International Journal of Urology" Also Showed Secondary Endpoints, Such as Onset of action in 15 Minutes and Percentage of Patients Reaching Normal Erectile Function According to the IIEF-EF Score NEW YORK, NY / ACCESSWIRE / September 8, 2022 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announces newly published third party data in the International Journal of Urology Efficacy and safety of avanafil as compared with sildenafil in the treatment of erectile dysfunction by Kumar, Pathade, Gupta, Goyal, Rath, Thakre, Sanmukhani, and Mittal, detailing the Company's PDE 5 inhibitor STENDRA® (avanafil) tablets in a non-inferiority, head-to-head study compared to sildenafil (Viagra) which was conducted in India. The primary efficacy endpoint was improvement in erectile function based on domain score of the International Index of Erectile Function (IIEF).

Internationally Published, Head-to-Head Data From India of Petros Pharmaceuticals' STENDRA(R) (Avanafil) Tablets Reported Improvement in Erectile Function Compared to Sildenafil and Baseline After 12 Weeks of Therapy

NEW YORK, NY / ACCESSWIRE / August 15, 2022 / Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announced financial results for the second quarter ended June 30, 2022. Highlights include: Reported Net Sales for Q2 of $4.2 million Achieved first positive quarter of Adjusted EBITDA over $200,000 Announced positive results of over-the-counter (OTC) label comprehension study for erectile dysfunction drug STENDRA® Engaged Massachusetts General Hospital (MGH) in sponsored research agreement for tissue-specific oxygenation sensor device technology Announced the Company is pursuing the 505(b)(2) pathway for its investigational agent H-100 for Peyronie's disease Launched social media campaign with celebrity Physician Dr. Drew Pinsky.

Petros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022

An absolutely incredible mover today, Petros Pharmaceuticals (NASDAQ: PTPI ) has seen some of the most impressive price action I've seen in some time. This morning, PTPI stock surged more than 260% on reports that the company would be acquired.

What Is Going on With Petros Pharmaceuticals (PTPI) Stock Today?

NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today confirmed that a press release issued on July 28, 2022 regarding a purported acquisition of the company was fraudulent and not issued by the Company. The Company is not a party to any such acquisition and has reported the fraudulent activity to Nasdaq.

Petros Pharmaceuticals Responds to Fraudulent Press Release

Petros Pharmaceuticals to become a privately-owned company operating independently as part of Henry Crown and Company's healthcare platform

Petros Pharmaceuticals to be Acquired by Henry Crown and Company for $3.25 per share

Dr. Drew to Raise Awareness of Petros Pharmaceuticals' Mission in The Men's Health Category and STENDRA® (avanafil) Dr. Drew to Raise Awareness of Petros Pharmaceuticals' Mission in The Men's Health Category and STENDRA® (avanafil)

Petros Pharmaceuticals Kicks Off Social Media Campaign with Celebrity Physician Dr. Drew Pinsky

NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced financial results for the first quarter ended March 31, 2022.

Petros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Company Is Developing H-100 as Potentially the First FDA-Approved, Nanoparticle-Based Topical Treatment Designed to Provide Improved and Sustained Local Medication Permeation Against Peyronie's Disease, Which is Currently Predominantly Treated Surgically, or by a Series of Injections Company Is Developing H-100 as Potentially the First FDA-Approved, Nanoparticle-Based Topical Treatment Designed to Provide Improved and Sustained Local Medication Permeation Against Peyronie's Disease, Which is Currently Predominantly Treated Surgically, or by a Series of Injections

Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company's Novel Topical Investigational Treatment for Peyronie's Disease Which Impacts More Than 1 in 10 Men in the US

NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will present virtually at the Planet MicroCap Showcase 2022. The conference is being held on May 3 – 5, 2022 at The Bally's Hotel & Casino in Las Vegas, NV.

Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022

Sensor Measures Oxygen Levels Within Specific Human Tissue, Potentially Allowing Biosensor Feedback of Erectile Device Therapy Sensor Measures Oxygen Levels Within Specific Human Tissue, Potentially Allowing Biosensor Feedback of Erectile Device Therapy

Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology

Borqs Technologies

Clarus Therapeutics Holdings

Can these penny stocks climb this coming week? The post 3 Hot Penny Stocks to Add to Your Small-Caps Watch List This Week  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Penny Stocks to Add to Your Small-Caps Watch List This Week

CYREN

China SXT Pharmaceuticals Inc

Are these strategies on your list for buying penny stocks next month? The post Best Penny Stocks, How To Buy & Strategies for Beginners appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks, How To Buy & Strategies for Beginners

Annexon, Inc

IT Tech Packaging Inc

Check these three penny stocks out for your watchlist The post What Are Penny Stocks? What You Need to Know and 3 to Watch  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What Are Penny Stocks? What You Need to Know and 3 to Watch

NEW YORK, April 01, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces financial results for the fiscal year ended December 31, 2021.

Petros Pharmaceuticals Reports Year End 2021 Financial Results and Corporate Highlights

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will present a corporate overview at the Q1 Investor Summit Conference, which is being held virtually on March 8 – 9, 2022.

Petros Pharmaceuticals to Present at the Q1 Investor Summit Conference

NEW YORK, Feb. 1, 2022 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces that it has signed a collaboration agreement with celebrity physician Dr. Drew Pinsky ("Dr. Drew") to raise awareness, foster dialogue, educate, and alleviate the stigma of erectile dysfunction (ED) and sexual dysfunction within the men's health and wellness landscape. Through this collaboration, Dr. Drew is expected to utilize his medical expertise and social media channels on behalf of Petros, to bring additional awareness to men's sexual health disparities, including potential available treatment options for these conditions.

Petros Pharmaceuticals Partners with Celebrity Physician Dr. Drew to Bring Awareness to Men's Health

Ocugen, Inc.

Splash Beverage Group

Singularity Future Technology

Are short squeeze penny stocks part of your strategy this week? The post Best Penny Stocks To Buy This Week?

Best Penny Stocks To Buy This Week? 4 Short Squeeze Stocks To Watch

NRX Pharmaceuticals

W&T Offshore

Reddit penny stocks to watch this week. The post 3 Reddit Penny Stocks For Your Watch List In January 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Reddit Penny Stocks For Your Watch List In January 2022

American Virtual Cloud Technologies

Insignia Systems

Reliance Global Group

Ensysce Biosciences

These five top short squeeze stocks are among the top speculative plays investors and traders are watching in today's market. The post Short Squeeze Stocks: ISIG, RELI and 3 Others Experts Think Are Ready to Pop appeared first on InvestorPlace.

Short Squeeze Stocks: ISIG, RELI and 3 Others Experts Think Are Ready to Pop

Potential short squeeze plays gained steam in 2021 with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidates To Watch: Insignia Systems, American Virtual Cloud Top List Again, Reliance Global Rejoins

Energy Focus

SeaChange International

Siyata Mobile Inc.

As the new year kicks off, investors are looking forward to another positive year in the markets. And interest in short squeeze stocks has not waned.

Short Squeeze Stocks: ISIG, AVCT and 5 Others Experts Think Are Ready to Pop

News for Petros Pharmaceuticals Stock (PTPI)